Cardiovascular risk factors in renal transplant recipients

International Journal of Artificial Organs

Volumn 23, Issue 11, 2000, Pages 730-735

  Elli, A ^a   Traversi, L ^a   Ponticelli, C ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIO-VASCULAR RISK FACTORS; RENAL TRANSPLANT RECIPIENTS;

AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR; CALCINEURIN INHIBITOR; CELL ADHESION MOLECULE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN A; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN; PREDNISOLONE; RAPAMYCIN; STATIN; STEROID; TACROLIMUS; TRIACYLGLYCEROL;

ALCOHOL CONSUMPTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DIABETES MELLITUS; DIALYSIS; DISEASE ASSOCIATION; DOSE RESPONSE; EDITORIAL; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERLIPIDEMIA; HYPERTENSION; INFECTION; INFLAMMATION; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIPOPROTEIN BLOOD LEVEL; LOW CALORY DIET; PHYSICAL ACTIVITY; RISK ASSESSMENT; RISK FACTOR; SMOKING CESSATION;

EID: 0034531354     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: 10.1177/039139880002301102     Document Type: Editorial

References (70)

1. Long-term survival in renal transplant recipients with graft function
2. Patient survival after renal transplantation: I. The impact of dialysis pre-transplant
3. Left ventricular hypertrophy
4. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention
5. Impact of hypertension on cardiomyopathy, morbidity and mortality in end-stage renal disease
6. Morbidity and mortality due to hypertension in patients with renal failure
7. Smoking and left ventricular hypertrophy (LVH) prior to renal transplantation (Tx) predict patients survival after Tx
8. A comparison of mortality between patients treated with hemodialysis and peritoneal dialysis
9. Comparison of long-term survival between hemodialysis and peritoneal dialysis
10. Cardiovascular morbidity and risk factors in renal transplant patients
11. Improved survival in patients with insulin-dependent diabetes mellitus and end-stage diabetic nephropathy 10 years after combined pancreas and kidney transplantation
12. Perspectives in diabetes: Diabetes and cardiovascular disease. The common soil hypotesis
13. Risk factors for cardiovascular disease in individuals with diabetes. The strong heart study
14. Insulin resistance in systemic hypertension: Pharmacotherapeutic implications
15. Pathophysiology of insulin resistance in human disease
16. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age
17. Diabetes mellitus after renal transplantation in the cyclosporine era - An analysis of risk factors
18. Possible role for calmodulin in insulin release: Studies with trifluoperazine in the rat pancreatic islets
19. Inhibition by cyclosporine of insulin secretion: A β cell specific alteration of islet tissue function
20. Are corticosteroids really necessary in renal transplantation?
21. Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancratic β cell
22. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation
23. Cardiovascular disease after renal transplantation
24. Possible causes and consequences of hypertension in stable renal transplant patients
25. Cause of arterial hypertension in kidney transplantation
26. Hypertension after transplantation
27. Hypertension in the transplantated patient
28. Multicenter randomized trial comparing tacrolimus (FK 506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
29. Hypertension after renal transplantation
30. Randomized controlled tiral of steroid withdrawal in renal transplant recipients receiving triple immunosuppression
31. Treatment of hypertension in renal allograft patients: Does drug selection make a difference?
32. Atherosclerosis. An inflammatory disease
33. Hyperlipidemia and glucose intolerance in the post-renal transplant patient
34. Atherosclerosis and lipid disorders after renal transplantation
35. Hyperlipidemia in solid organ transplantation
36. Oxidation of low density lipoproteins from patients with renal failure and renal transplants
37. Does Cyclosporine increase lipoprotein (a) concentrations in renal transplant recipients?
38. Cyclosporine and serum lipids in renal transplant recipients
39. Lipid abnormalities in cyclosporine-treated renal transplant recipients
40. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group
41. Oxydative stress and cardiovascular disease
42. Role of lipid disturbances in the atherosclerosis of renal transplant patients
43. Plasma homocysteine, a risk factor for vascular disease: Plasma levels in health, disease and drug therapy
44. Prospective studies of homocysteine and cardiovascular disease
45. Post-transplant hyperlipidemia: Mechanisms and management
46. Excess prevalence of fasting and postmethionine loading hyperhomocysteinemia in stable renal transplant recipients
47. Serum total homocysteine concentration before and after renal transplantation
48. Serum total homocysteine does not predict outcome in renal transplant recipients
49. Serum total homocysteine and cadiovascular disease occurrence in chronic, stable renal transplant recipients: A prospective study
50. Hyperhomocysteinemia: A significant risk factor for cardiovascular disease in renal transplant recipients
51. Homocysteine in the plasma of renal transplant recipients: Effects of cofactors for methionine metabolism
52. Hyperhomocysteinemia in chronic renal disease
53. Hyperhomocysteinemia in cyclosporine treated renal transplant recipients
54. Hyperhomocysteinemia in renal transplant recipients with and without cyclosporine
55. A candidate genetic risk factor for vascular disease. A common mutation in methylenetetrahydrofolate reductase
56. Thermolabile defect of methylenetetrahydrofolate reductase. An inherited risk factor for coronary artery disease
57. Effect of MTHFR 677 C>T on plasma total homocysteine levels in renal graft recipients
58. Biologic markers as predictors of cardiovascular disease
59. Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients
60. Elevated plasminogen activator inhibitor levels in cyclosporine-treated renal allograft recipients
61. Enhancement of human platelet aggregation and secretion induced by rapamycin
62. Cellular adhesion molecules and atherogenesis
63. Levels of soluble cell adhesion molecules in patients with dyslipidemia
64. Cigarette smoke condensate-induced adhesion molecule expression and transendothelial migration of monocytes
65. Variation in expression of endothelial adhesion molecules in retransplant and transplanted kidneys: Correlation with intragraft events
66. Cell adhesion molecules in clinical renal transplantation
67. Infection and inflammation as risk factors for myocardial infarction
68. Cytomegalovirus infection enhances the neointima formation in rat aortic allograft
69. Patient survival after renal transplantation: II. The impact of smoking
70. A randomized study comparing three cyclosporine-based regimens in cadaveric renal transplantation